Aptevo reports 93% clinical benefit rate in frontline AML
Aptevo reported a 93% clinical benefit rate for mipletamig with venetoclax and azacitidine in evaluable frontline TP53-mutated AML patients.
Aptevo reported a 93% clinical benefit rate with mipletamig combined with venetoclax and azacitidine in evaluable frontline TP53—mutated AML patients.Key Highlights:Original SEC Filing: Aptevo Therapeutics Inc. [ APVO ] - 8-K - Sep. 03, 2026This is an AI-powered summary. It may contain inaccuracies…